- Home
- VNO vs ROIV Comparison
VNO vs ROIV Comparison
Compare VNO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNO
- ROIV
- Stock Information
- Founded
- VNO 1946
- ROIV 2014
- Country
- VNO United States
- ROIV United Kingdom
- Employees
- VNO N/A
- ROIV N/A
- Industry
- VNO Real Estate Investment Trusts
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- VNO Real Estate
- ROIV Health Care
- Exchange
- VNO Nasdaq
- ROIV Nasdaq
- Market Cap
- VNO 7.3B
- ROIV 8.6B
- IPO Year
- VNO N/A
- ROIV N/A
- Fundamental
- Price
- VNO $42.12
- ROIV $15.10
- Analyst Decision
- VNO Hold
- ROIV Strong Buy
- Analyst Count
- VNO 11
- ROIV 4
- Target Price
- VNO $38.64
- ROIV $15.50
- AVG Volume (30 Days)
- VNO 2.1M
- ROIV 7.8M
- Earning Date
- VNO 11-03-2025
- ROIV 11-11-2025
- Dividend Yield
- VNO 1.80%
- ROIV N/A
- EPS Growth
- VNO 4453.28
- ROIV N/A
- EPS
- VNO 4.07
- ROIV N/A
- Revenue
- VNO $1,889,783,000.00
- ROIV $23,233,000.00
- Revenue This Year
- VNO N/A
- ROIV N/A
- Revenue Next Year
- VNO $2.94
- ROIV $281.14
- P/E Ratio
- VNO $10.11
- ROIV N/A
- Revenue Growth
- VNO 0.58
- ROIV N/A
- 52 Week Low
- VNO $29.68
- ROIV $8.73
- 52 Week High
- VNO $46.63
- ROIV $16.05
- Technical
- Relative Strength Index (RSI)
- VNO 61.50
- ROIV 78.92
- Support Level
- VNO $41.06
- ROIV $13.81
- Resistance Level
- VNO $42.50
- ROIV $16.05
- Average True Range (ATR)
- VNO 1.11
- ROIV 0.49
- MACD
- VNO 0.25
- ROIV 0.22
- Stochastic Oscillator
- VNO 79.48
- ROIV 78.21
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.